CJC-1295
Also known as CJC-1295 without DAC · Mod GRF 1-29 · CJC-1295 with DAC
New
Reconstitution & dosing guide
2 mg · 5 mg · 10 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
CJC 1295 (without DAC) (CND10) · Not in current stock
$35 / vial
2mg x 10 vials
CJC 1295 (without DAC) (CND2) · Not in current stock
$15 / vial
5mg x 10 vials
CJC 1295 (without DAC) (CND5) · Not in current stock
$20 / vial
Prices per vial · Research use only · Not medical advice.
GHRH analog that stimulates natural growth-hormone pulses; used with GHRPs for body composition and recovery goals.
How to picture it
Your hypothalamus normally sends GHRH pulses that tell the pituitary "release growth hormone now." CJC-1295 is a stabilized GHRH-family message that knocks on that same pituitary door. With DAC it wears a long "stay in circulation" backpack so the signal lingers for days; without DAC it behaves more like a timed doorbell — pulse, then quiet. The educational picture is axis engagement: ask the pituitary to release GH, rather than injecting finished growth hormone, with a design choice between physiologic rhythm and sustained elevation.
Research focus & benefits
- Endogenous GH pulse or sustained GH/IGF-1 elevation research
- Pairs with GHRPs for larger pulse amplitude studies
- Sleep, recovery, and body-composition pathway interest
- More physiologic framing than exogenous rHGH replacement
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
CJC-1295 is a modified growth hormone–releasing hormone (GHRH) analog. Two forms circulate in research markets: without DAC (often called Mod GRF 1-29; short-acting, pulse-like) and with DAC (Drug Affinity Complex; longer-acting). Biohackers typically prefer the no-DAC form with Ipamorelin to mimic physiologic GH pulses rather than flat elevation.
Mechanism
Binds GHRH receptors on pituitary somatotrophs, increasing GH secretion. With DAC, albumin binding extends half-life; without DAC, effects are short and better timed with sleep or training.
Research uses
- GH deficiency research models
- Body composition studies
- Aging and recovery research contexts
Research dosing notes
Common community practice: no-DAC CJC-1295 + Ipamorelin before bed, sometimes post-workout. DAC forms are less popular due to non-physiologic GH elevation and side-effect reports.
Half-life / kinetics
No DAC: ~30 minutes; With DAC: multi-day
Common research routes
Reported considerations
- Water retention
- Tingling / numbness
- Increased hunger (more with some GHRPs)
- Possible IGF-1 elevation concerns long-term
Contraindications / cautions
- Active cancer
- Uncontrolled diabetes
- Pregnancy
- Proliferative retinopathy risk
Common research stacks
- Ipamorelin
- GHRP-2
- Tesamorelin
- BPC-157
Legal / access note
Not FDA-approved. Related GHRH analogs have clinical history, but CJC-1295 research products are typically unapproved.